Related to Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera

• GenVec and Novartis Cement Hearing Loss Partnership with Manufacturing Deal
  
• Novartis Shells Out $10M for Option to Quark’s Phase II-Stage Synthetic siRNA
  
• Warner Chilcott Acquires Sole U.S. Rights to Novartis’ Marketed Overactive Bladder Drug for $400M
  
• Alnylam to Nix Jobs in the Wake of Novartis Collaboration Ending
  
• Novartis and HGS Ditch HCV Drug as EMEA and FDA Express Risk-Benefit Concerns
  
• Novartis Teams with Synthetic Genomics Vaccines to Develop Flu Seed Virus Banks
  
• Novartis Inks U.S. Commercialization Deal for Cepheid’s Ph+ CML Prognostic Tool
  
• Incyte Earns $19M Milestone from Lilly on Start of Phase IIb Trial with RA Candidate
  
• Antisoma and Novartis Ditch ASA404 After Second Phase III NSCLC Trial Bombs
  
• IP-K Extends Collaborations with Sanofi-Aventis R&D and Novartis Tropical Disease Institute
  
• Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results
  
• Novartis to Assess Quanterix’ Single Molecule Array Platform for Diagnostic Use
  
• Novartis Pays GW Pharm $5M Up Front for Sativex Rights in Multiple Territories
  
• Novartis and Vectura Confirm Positive Data from First Phase III Study with COPD Drug
  
• Novartis Pays Enanta $34M Up Front for Worldwide Rights to HCV NS5A Inhibitors
  
• Vectura, Novartis' COPD Therapy Succeeds in Fourth Phase III Study
  
• Novartis Pays Genmab $2M to Tap into Bispecific Antibody Technology
  
• Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral Gene Therapy
  
• Second Phase III Study Shows Incyte and Novartis Drug Reduces Spleen Size in Myelofibrosis
  
• Novartis Shells Out $210M for Two of Incyte’s Hematology-Oncology Candidates